Targeted drug extends survival in CLARITY-Gastric01
In CLARITY-Gastric01, sonesitatug vedotin prolonged overall survival versus the comparison treatment in selected, previously treated patients with advanced gastric or gastroesophageal cancer carrying CLDN18.2. The result was presented at ESMO. The trial did not meet its other main endpoint concerning disease progression, and its findings do not apply to every gastric cancer patient. Adverse effects also matter when assessing this investigational drug.
Science··Morning
Survival rose in a defined patient group
CLARITY-Gastric01, presented in Madrid, compared sonesitatug vedotin with other treatment in previously treated advanced gastric and gastroesophageal cancer. The enrolled patients had tumours carrying the CLDN18.2 surface target. The investigational medicine delivers a drug payload through an antibody and showed an overall-survival benefit. This result does not establish the same benefit in tumours without the target or in patients starting first-line treatment.[1], [2]
The progression endpoint was missed
The other main endpoint, concerning disease progression, was not met despite the survival benefit. Lifespan, tumour response and time without progression answer different questions. Outcomes for later treatment lines and the full enrolled population were considered separately. Subgroup observations according to target expression do not provide equally certain conclusions for every smaller patient group. These clinical distinctions add detail to the earlier positive topline announcement.[1]
Adverse effects remained part of the trial
Nausea, vomiting and reduced appetite were more frequent with the conjugate, while some severe blood-cell problems were more prominent under comparator treatments. Both approaches involved delays, dose reductions or discontinuations attributed to adverse effects. The benefit and harm findings concern a particular tumour feature and treatment history. A congress presentation does not itself mean the investigational product has received approval in every country or has become a standard for all gastric cancers.[1]
